On October 19th will be held the Ion world tour, in which Genetracer Biotech will act as a speaker talking about the liquid biopsy in cancer diagnosis: ctDNA vs FFPE in colorectal cancer.
Genetracer Biotech will be present from September 26 to 29 at the Brazilian Congress of Clinical Pathology, offering a session of the use of the liquid biopsy in the oncological diagnosis by Dr. Patricia Ruiz-Ontañon.
Genetracer Biotech has obtained the certificate of excellence from the European Commission rating the project proposal as high quality in a highly competitive evaluation process.
The Liquid Biopsy has been ranked among the top 10 emerging technologies in 2017 by the World Economic Forum panel of experts.
On June 16, 2017 Genetracer Biotech received the "Cantábrico Excelente" Award 2017 in the category of Sanitary Technology. Read more
Genetracer Biotech will be present, Between the days 19 and 22 of June, in the BIO INTERNATIONAL CONVENTION 2017 which is held in San Diego. Through the following link you can see our location.
Genetracer Biotech participated in 2016 in the European Molecular Genetics Quality Network (EMQN) whith two external quality assessment schemes: NextGen DNA Sequencing (vGermline) NextGen DNA Sequencing (vSomatic) Both of them where passed with satisfactory result.
Fluxion Biosciences Appoints Genetracer Biotech of Spain As an Isoflux Liquid Biopsy Certified Service Provider
Genetracer Biotech will utilize Fluxion's IsoFlux circulating tumor cell (CTC) system to provide NGS-based liquid biopsy services for lung and colon cancers. More information
Genetracer Biotech participates as a company committed to training students in the Scholarship Program Practices in SMEs Santander Santander CRUE CEPYME 2016. The program is designed to complement the training of students of Spanish universities approaching them the reality of the professional field expanding [...]
Source: El Diario Montañés Genetracer Biotech participated last Wednesday 6th in the Technology Days organized by El Diario. Dr. Carlos Cortijo, CEO of the company Genetracer Biotech, defended the idea of the passage of traditional biopsy to the new liquid biopsy. He said in his [...]